Catalent opens second clinical supply facility in Shanghai

Shanghai
Catalent has opened a new facility in Shanghai to serve drug developers in the region. (Pixabay)

With drug development among both Chinese and Western biotechs and drugmakers escalating rapidly, Catalent has doubled down on its clinical supply capabilities in Shanghai.

The Somerset, New Jersey-based company has opened a new 30,000-square-foot clinical supply facility outside the free trade zone in Tangzhen, near Catalent’s existing Waigaoqiao free trade zone site and China’s Zhangjiang Pharma Valley area.

The facility, which will employ up to 100 workers, has capabilities to provide supply, secondary packaging, clinical storage and local distribution, as well as clinical returns and destruction services, the company said.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Roel de Nobel, VP of global operations for Catalent Clinical Supply Services, said in a statement that “having facilities both inside and outside” the free trade zone gives some flexibility to the growing numbers of drug developers in the region.

Catalent also has recently made investments in clinical supply manufacturing in Singapore and Japan.  

There have been extensive drug manufacturing investments in and around China as that country aggressively works to bring new generation drugs to consumers. Last fall, Rockville, Maryland-based CASI announced it was building a new manufacturing site at the Wuxi Huishan Economic Development Zone in Jiangsu Province, China.

CASI, which has focused much of its drug development efforts there, last year bought from Sandoz four pipeline ANDAs that are pending FDA approval. Among those is entecavir, an antiviral treatment for hepatitis B, which is a significant problem in China.

Suggested Articles

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.